Mirikizumab - Intravenous (IV)

Phase 2

Eli Lilly

Mirikizumab - Intravenous (IV) is one of 22 therapeutic programs targeting Crohn Disease. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Crohn DiseaseRecruiting

Colitis, UlcerativeRecruiting

Crohn DiseasePhase 2

Recruiting

Colitis, UlcerativePhase 2

Recruiting

Competition

Competitive Landscape

20 competitors in Colitis, Ulcerative

#DrugCompanyPhaseTrials

Tremfya

Johnson & Johnson

Phase 3

4 2

Simponi

Johnson & Johnson

Phase 3

2 3

Icotyde

Johnson & Johnson

Phase 3

1 4

Remicade

OOrganon and Co

Phase 3

1 5

Velsipity

Pfizer

Phase 2

3 6

JNJ-78934804

Johnson & Johnson

Phase 3

2 7

Dupixent

AAzienda U.S.L. 1 di Massa e Carrara

Phase 2

1 8

Guselkumab Dose 1

Johnson & Johnson

Phase 3

1 9

Guselkumab Dose 2

Johnson & Johnson

Phase 3

1 10

Guselkumab Dose 3

Johnson & Johnson

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2028

Phase 2Recruiting

Colitis, Ulcerative

NCT07483073

Phase 2Recruiting

Crohn Disease

NCT07483099

Clinical

Trials by Indication[1]

Colitis, Ulcerative1 trial

A Master Protocol for Phase 2, Randomized, Controlled Studies of Multiple Interventions for the Treatment of Adults With Moderately to Severely Active Ulcerative Colitis or Crohn's Disease

Recruiting· Eli Lilly logo

Eli Lilly·Phase 2·NCT07483073·60 enrolled

Crohn Disease1 trial

A Phase 2, Multicenter, Randomized, Open-Label, Active-Controlled Study to Investigate LY4395089/Mirikizumab Co-administration Compared With Mirikizumab in Adults With Moderately to Severely Active Crohn's Disease

Recruiting· Eli Lilly logo

Eli Lilly·Phase 2·NCT07483099·60 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Mirikizumab - Intravenous (IV). U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Mirikizumab - Intravenous (IV). EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Eli Lilly company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 2[1]
Company: Eli Lilly

Mirikizumab - Intravenous (IV)

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q1 2028

Trials by Indication[1]

Colitis, Ulcerative1 trial

Crohn Disease1 trial

References

Drug Info

Quick Facts

Related News